Home | All trials

[RDF data]
Trial NCT00000483

Resource URI: http://static.linkedct.org/resource/trials/NCT00000483
PropertyValue
linkedct:brief_title Coronary Drug Project Mortality Surveillance
linkedct:condition <http://static.linkedct.org/resource/condition/2312>
linkedct:condition <http://static.linkedct.org/resource/condition/3388>
linkedct:condition <http://static.linkedct.org/resource/condition/5702>
linkedct:condition <http://static.linkedct.org/resource/condition/8483>
linkedct:condition <http://static.linkedct.org/resource/condition/8489>
linkedct:criteria No eligibility criteria
linkedct:description BACKGROUND: Three of the CDP treatments (two doses of estrogen and dextrothyroxine) were stopped prematurely because of toxicity. At the time the treatments were stopped, it was thought that future assessment of the status of patients on those treatments would be important to evaluate long-term sequellae. Another clinical trial evaluating clofibrate for primary prevention found that more patients on that treatment than on placebo had died. This effect persisted even after the treatment was stopped. Therefore, it was considered necessary to follow the CDP patients on clofibrate. Of the original 834l patients, about 6000 were still alive in March l975. Cause-specific mortality in those patients was assessed through March l980. DESIGN NARRATIVE: The vital status of the subjects known to be alive at the end of the CDP in March l975 was assessed as of March l980. This was accomplished through questioning the local investigators, letters to the subjects, and by use of Social Security Administration and National Death Index records.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Male
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 64 Years
linkedct:eligibility_minimum_age 30 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 27, 1999
linkedct:id NCT00000483
rdfs:label Trial NCT00000483
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Heart, Lung, and Blood Institute (NHLBI)
linkedct:nct_id NCT00000483
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id 2
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/51512>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000483>
linkedct:phase N/A
linkedct:reference <http://static.linkedct.org/resource/reference/38040>
linkedct:reference <http://static.linkedct.org/resource/reference/41725>
linkedct:reference <http://static.linkedct.org/resource/reference/43743>
linkedct:reference <http://static.linkedct.org/resource/reference/43744>
linkedct:source National Heart, Lung, and Blood Institute (NHLBI)
linkedct:start_date June 1981
linkedct:study_design Prevention, Randomized
linkedct:study_type Interventional
linkedct:summary To determine whether there were any long term sequelae of the drugs used in the Coronary Drug Project (estrogens, dextrothyroxine, nicotinic acid, clofibrate).
rdf:type linkedct:trials
linkedct:verification_date April 2004